Metabolic Disorders Drugs Market covering Anti Diabetics drugs; Anti-Thyroid drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); Global Briefing 2019
North America was the largest region in the metabolic disorders drugs market worth $35.2 billion in 2018, accounting for 53.5% of the global metabolic disorders drugs market, followed by Western Europe at 19.7% and Asia Pacific at 16.6% respectively.
Metabolic Disorders Drugs Market covering Anti Diabetics drugs; Anti-Thyroid drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); Global Briefing 2019 provides strategists, marketers and senior management with the critical information they need to assess the global metabolic disorders drugs sector.
Reasons to Purchase
- Fully updated for 2019.
- Identify growth segments and opportunities.
- Facilitate decision making on the basis of historic and forecast data and understand the drivers and restraints on the market.
- Develop strategies based on likely future developments.
- Gain a global perspective on the development of the market.
Metabolic Disorders Drugs Market covering Anti Diabetics drugs; Anti-Thyroid drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); Global Briefing 2019 from the Business Research Company covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for this market.
The market characteristics section of the report defines and explains the market.
The market size section gives the metabolic disorders drugs market revenues, covering both the historic growth of the market and forecasting the future.
Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
Market segmentations break down the key sub sectors which make up the market. The regional breakdowns section gives the size of the market geographically.
Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in the last three years are identified.
The trends and strategies section highlights the likely future developments in the metabolic disorders drugs market and suggests approaches.
Markets Covered: Anti Diabetics drugs; Anti-Thyroid drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)
Companies Mentioned: Sanofi S.A.; Eli Lilly And Company; Merck & Co.; Novo Nordisk; Astrazeneca
Geographic scope: Asia Pacific, North America, Western Europe, Eastern Europe, South America, Middle East, Africa
Countries: Australia, China, Hong Kong, India, Indonesia, Japan, South Korea, Malaysia, New Zealand, Philippines, Singapore, Thailand, Vietnam, Canada, USA, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela, Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, the UK, Czech Republic, Poland, Romania, Russia, Israel, Saudi Arabia, Turkey, UAE, Egypt, Nigeria, South Africa
Time series: Five years historic and forecast
Data: Market value in $ billions.
Data segmentations: Regional breakdowns, market share of competitors, key sub segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.